Idelalisib--a PI3Kδ inhibitor for B-cell cancers

N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Male
  • Phosphoinositide-3 Kinase Inhibitors*
  • Purines / therapeutic use*
  • Quinazolinones / therapeutic use*
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines
  • Quinazolinones
  • Rituximab
  • idelalisib